Lisa Minor

Title: The Innovative Contributions of Lisa Minor in Urotensin II Research

Introduction

Lisa Minor is an accomplished inventor based in Flemington, NJ, known for her significant contributions to the field of biological activity measurement related to urotensin II receptors. With a total of two patents to her name, Minor's research plays a crucial role in advancing understanding in pharmacology and therapeutic applications.

Latest Patents

Lisa Minor's latest patents focus on innovative methods involving urotensin II receptors. The first patent describes a "Method of measuring the biological activity of an urotensin II receptor." This invention demonstrates that the administration of urotensin II (U-II) to rats results in increased redness or skin temperature in their ears. Importantly, these changes can be inhibited by compounds that reduce the biological activity of the U-II/UT receptor, thereby providing insights into measuring receptor activity through observable physical changes.

The second patent, titled "Human cell clones having an endogenous urotensin II receptor," presents human cell clones that exhibit increased specific binding to urotensin II. These clones, derived from SJRH30, are pivotal for functional analyses regarding the biological activity of urotensin II receptors and aid in identifying compounds that influence this activity.

Career Highlights

Lisa currently works at Janssen Pharmaceutica, a global leader in pharmaceutical innovation. Her work is particularly focused on developing novel approaches to better understand and manipulate biological receptors, enhancing the landscape of drug discovery and development.

Collaborations

Throughout her career, Lisa has collaborated with talented colleagues, including Robert Schulingkamp and Jianshen Qi. These partnerships foster an environment of creative problem-solving and innovative thinking, contributing to her successful patent filings and research initiatives.

Conclusion

Lisa Minor is a prominent figure in the field of pharmacological research, with impactful patents that pave the way for future advancements in understanding urotensin II receptors. As she continues her work at Janssen Pharmaceutica, her contributions will undoubtedly influence the direction of research and therapeutic development in this crucial area of study.